Previous 10 | Next 10 |
Unique Mechanism of Action Suppresses Inflammation and Immune Activation Without Promoting Pro-Inflammatory Lymphocyte Stimulation Preliminary Phase 1 Data Read-outs Anticipated Q3 and Q4 2019 SEATTLE, March 20, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO)...
Aptevo Therapeutics (NASDAQ: APVO ): FY GAAP EPS of -$2.39. More news on: Aptevo Therapeutics Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, , Read more ...
Achieves Record Annual IXINITY ® Net Revenue of $23.1 Million Representing 111% Increase Over 2017 Advances APVO436 Into Phase 1/1b Clinical Trial for Treatment of Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome Receives Authorization to Commence ...
Gainers: Bio-Path Holdings (NASDAQ: BPTH ) +201% . Seelos Therapeutics (NASDAQ: SEEL ) +79% . ArQule (NASDAQ: ARQL ) +66% . Altimmune (NASDAQ: ALT ) +60% . Rosetta Stone (NYSE: RST ) +31% . Calumet Specialty Products Partners (NASDAQ: CLMT ) +29% . Cleveland BioLabs (NASDAQ: CB...
Aptevo Therapeutics ( APVO -45.1% ) slumps on almost 13x higher volume in response to its public offering of 19.85M shares of common stock and warrants to purchase up to the same number of shares at a price of $1.00 per share and warrant. More news on: Aptevo Therapeutics Inc., Healthc...
Aptevo Therapeutics (NASDAQ: APVO ) -38% on equity offering . More news on: Aptevo Therapeutics Inc., Resideo Technologies, Inc., Kroger Co., Stocks on the move, Read more ...
SEATTLE, March 07, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology, autoimmune and hematology therapeutics, today announced the pricing of (i) for a combined public offering price of $1.00 per share of common sto...
SEATTLE, March 06, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology, autoimmune and hematology therapeutics, today announced that it intends to offer and sell, subject to market and other conditions, shares of its...
ADAPTIR™ Bispecific Antibody Candidates Poised to Progress in Clinical Development APVO436 Advancing in Phase 1 Clinical Trial for Acute Myeloid Leukemia; APVO210 Beginning Phase 1 Clinical Trial in Q1 2019; ALG.APV-527 Progressing with CTA Submission in H2 2019 Project...
Provides Opportunistic Capital of up to $35 Million to Aptevo During the 36-month Term of the Agreement SEATTLE, Dec. 21, 2018 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, announced...
News, Short Squeeze, Breakout and More Instantly...
Aptevo Therapeutics Inc. Company Name:
APVO Stock Symbol:
NASDAQ Market:
Aptevo Therapeutics Inc. Website:
A look at the top 10 most actives in the United States Onconetix Inc. (ONCO) rose 113.3% to $0.3178 on volume of 162,323,665 shares NVIDIA Corporation (NVDA) rose 0.8% to $118.92 on volume of 44,858,282 shares Maxeon Solar Technologies Ltd. (MAXN) rose 8.5% to $0.2648 on volume of 43,008,...
2024-07-18 06:16:00 ET 3 Tips for Using RSI When Investing in Penny Stocks Relative Strength Index (RSI) is a powerful tool for evaluating the momentum of stocks, and it can be particularly effective when investing in penny stocks . Penny stocks offer unique opportunities due to the...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 6.6% to $117.99 on volume of 383,510,118 shares Aptevo Therapeutics Inc. (APVO) rose 73.4% to $0.581 on volume of 315,289,581 shares PROSHARES TRUST (SQQQ) rose 8.7% to $8.11 on volume of 173,682,364 sha...